{{Rsnum
|rsid=2228622
|Gene=SLC1A1
|Chromosome=9
|position=4564432
|Orientation=plus
|GMAF=0.3108
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(A;A)
|geno2=(A;G)
|geno3=(G;G)
|Gene_s=SLC1A1,SPATA6L
}}{{ population diversity
| geno1=(A;A)
| geno2=(A;G)
| geno3=(G;G)
| CEU | 19.5 | 46.9 | 33.6
| HCB | 7.3 | 32.1 | 60.6
| JPT | 3.5 | 40.7 | 55.8
| YRI | 4.1 | 27.2 | 68.7
| ASW | 3.5 | 36.8 | 59.6
| CHB | 7.3 | 32.1 | 60.6
| CHD | 9.2 | 31.2 | 59.6
| GIH | 21.8 | 58.4 | 19.8
| LWK | 1.8 | 36.7 | 61.5
| MEX | 15.5 | 53.4 | 31.0
| MKK | 9.6 | 40.4 | 50.0
| TSI | 19.6 | 49.0 | 31.4
| HapMapRevision=28
}}{{PMID Auto
|PMID=19884611
|Title=Association of the glutamate transporter gene SLC1A1 with atypical antipsychotics-induced obsessive-compulsive symptoms
}}

{{PharmGKB
|RSID=rs2228622
|Name_s=SLC1A1:rs2228622G>A, SNP2, Exon 4(syn)
|Gene_s=SLC1A1
|Feature=
|Evidence=PubMed ID:19884611
|Annotation=Risk or phenotype-associated variant: A. Phenotype: The A/C/G haplotype at rs2228622-rs3780413-rs3780412 showed a significant association with atypical antipsychotic-induced obsessive compulsive symptoms. Study size: 94. Study population/ethnicity: Patients with schizophrenia receiving atypical antipsychotics; Asian; Korea. Significance metric(s): p = 0.04. Type of association: CO.
|Drugs=clozapine; olanzapine; risperidone
|Drug Classes=
|Diseases=Obsessive-Compulsive Disorder; Schizophrenia
|Curation Level=Curated
|PharmGKB Accession ID=PA165110321
}}

{{PMID Auto
|PMID=21990008
|Title=Interaction between genetic variants of DLGAP3 and SLC1A1 affecting the risk of atypical antipsychotics-induced obsessive-compulsive symptoms.
}}

{{PMID Auto
|PMID=17894418
|Title=Association of the SLC1A1 glutamate transporter gene and obsessive-compulsive disorder.
}}

{{PMID Auto
|PMID=21124337
|Title=Evidence for epistatic interactions in antiepileptic drug resistance.
}}

{{PMID Auto
|PMID=22531293
|Title=Polymorphisms in the glutamate transporter gene SLC1A1 and obsessive-compulsive symptoms induced by second-generation antipsychotic agents.
}}

{{GET Evidence
|impact=pharmacogenetic
|qualified_impact=Insufficiently evaluated pharmacogenetic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs2228622
|overall_frequency_n=3781
|overall_frequency_d=10758
|overall_frequency=0.351459
|n_genomes=30
|n_genomes_annotated=0
|n_haplomes=38
|n_articles=1
|n_articles_annotated=0
|in_pharmgkb=Y
|autoscore=1
|webscore=N
}}

{{PMID Auto
|PMID=23564280
|Title=Association between SLC1A1 gene and early-onset OCD in the Han Chinese population: a case-control study.
}}

{{PMID Auto
|PMID=23660601
|Title=Influence of polymorphisms in genes SLC1A1, GRIN2B, and GRIK2 on clozapine-induced obsessive-compulsive symptoms.
}}

{{PMID Auto
|PMID=23411042
|Title=Association of the candidate gene SLC1A1 and obsessive-compulsive disorder in Han Chinese population
}}
{{on chip | 23andMe v2}}
{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | Affy GenomeWide 6}}
{{on chip | FTDNA2}}
{{on chip | HumanOmni1Quad}}
{{on chip | Illumina Human 1M}}